CellCept

(Mycophenolate Mofetil)

ApprovedSmall molecule

Mycophenolate mofetil is used to prevent the body's immune system from rejecting transplanted organs like kidneys, hearts, or livers. It's also used to treat certain autoimmune diseases where the immune system attacks the body's own tissues.[2] CellCept is currently approved and in use across 113 indications[4].[1]

CellCept is one of 1813 small molecule programs targeting HIV infection. It is currently in Approved.

113

Indications

616

Total Trials

Active Trials

1,812

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusApproved

GranulomaActive, not recruiting

Cardiovascular DiseaseApproved

Pemphigus VulgarisApproved

Left Ventricular HypertrophyActive, not recruiting

Aplastic AnemiaActive, not recruiting

ArthritisActive, not recruiting

Liver TransplantApproved

ToxicityActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Systemic Lupus ErythematosusApproved

Approved

GranulomaPhase 1

Active, not recruiting

Cardiovascular DiseaseApproved

Approved

Pemphigus VulgarisApproved

Approved

Left Ventricular HypertrophyApproved

Active, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

ArthritisPhase 1/Phase 2

Active, not recruiting

Liver TransplantApproved

Approved

ToxicityPhase 2

Active, not recruiting

Showing 10 of 113 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

CellCept

Roche

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Spravato

WWim Janssens

Preclinical

2 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Stem Cell Transplant

NCT02861417

Phase 2Recruiting

Heart Transplantation

NCT04477629

Q4 2026

Post-ApprovalActive, not recruiting

Kidney Transplant

NCT05193565

Phase 2Active, not recruiting

Hematopoietic Cell Transplantation

NCT04904588

Phase 2Recruiting

Non-Malignant Disorders

NCT04644016

Q1 2027

Phase 2Recruiting

Lupus Nephritis

NCT05538208

Clinical

Trials by Indication[1]

Kidney Transplant20 trials

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Completed·MMedical University of South Carolina·N/A·NCT02954198·40 enrolled

MMF vs. AZA for Kidney Transplantation

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT00494741·233 enrolled

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00790439

Show 17 more trials

Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation

Completed· Astellas logo

Astellas·Phase 3·NCT00693381·152 enrolled

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

Completed· Astellas logo

Astellas·Phase 3·NCT00064701·668 enrolled

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01790594·46 enrolled

Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation

Completed·NNova Scotia Health Authority·Phase 4·NCT00943228·40 enrolled

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00240994·35 enrolled

A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant

Completed· Sanofi logo

Sanofi·Phase 4·NCT03099122·115 enrolled

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Completed· Novartis logo

Novartis·Phase 2·NCT03663335·418 enrolled

Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation

Completed· Astellas logo

Astellas·Phase 4·NCT01742624·60 enrolled

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed·JJohns Hopkins University·Phase 3·NCT00275509·56 enrolled

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

Active, not recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT05193565·206 enrolled

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Completed·MMayo Clinic·Phase 4·NCT00275535·165 enrolled

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Unknown status·LLee's Pharmaceutical Limited·Phase 4·NCT06114953·152 enrolled

Veloxis de Novo Kidney Transplant ECSWD

Unknown status·SSimon Tremblay, PharmD, PhD·Phase 4·NCT03828682·60 enrolled

A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation

Completed· Roche logo

Roche·Phase 4·NCT00817687·66 enrolled

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Completed· Astellas logo

Astellas·Phase 2·NCT01780844·149 enrolled

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Unknown status·TTolera Therapeutics, Inc·Phase 1/2·NCT01154387·85 enrolled

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Completed· Novartis logo

Novartis·Phase 4·NCT00239005·134 enrolled

Lupus Nephritis9 trials

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Completed·—·Phase 3·NCT01042457·24 enrolled

Multicenter Registry of Pediatric Lupus Nephritis in China

Unknown status·XXiqiang Dang··NCT03791827·1,200 enrolled

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Terminated· EMD Serono logo

EMD Serono·Phase 2/3·NCT00573157·6 enrolled

Show 6 more trials

Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis

Withdrawn·—·Phase 2·NCT05101447

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.

Completed·FFrédéric A. Houssiau, MD, PhD·Phase 3·NCT00204022·105 enrolled

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Recruiting·—·Phase 2·NCT05538208·105 enrolled

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03943147·16 enrolled

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01714817·695 enrolled

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00430677·423 enrolled

Liver Transplant9 trials

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

Terminated·—·Phase 4·NCT00656266·13 enrolled

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

Completed· Astellas logo

Astellas·Phase 3·NCT01011205·893 enrolled

Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation

Withdrawn·UUniversity of Wisconsin, Madison·N/A·NCT00849238

Show 6 more trials

Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00007059·20 enrolled

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00105235·27 enrolled

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00374231·40 enrolled

A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.

Completed· Roche logo

Roche·Phase 4·NCT00717314·87 enrolled

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Completed· Roche logo

Roche·Phase 4·NCT00118742·293 enrolled

Belatacept in Liver Transplant Recipients

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00555321·260 enrolled

Stem Cell Transplant8 trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00317785·50 enrolled

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

Show 5 more trials

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00006251·21 enrolled

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00112593·5 enrolled

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053196·82 enrolled

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02861417·204 enrolled

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00230035

Hematologic Malignancies5 trials

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01341301·25 enrolled

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02199041·24 enrolled

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01175785·15 enrolled

Show 2 more trials

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Completed·FFred Hutchinson Cancer Center·N/A·NCT00014235·160 enrolled

93 more indications

Hematologic Cancer4 trials

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Terminated·UUniversity of Rochester·N/A·NCT00255684·16 enrolled

Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290641·68 enrolled

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00301951·7 enrolled

Show 1 more trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00723099·73 enrolled

Fed4 trials

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT00893958·39 enrolled

Mycophenolate Mofetil Tablets Under Fed Conditions

Completed· Teva logo

Teva·Phase 1·NCT00908128·40 enrolled

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions

Completed·—·Phase 1·NCT01513057·61 enrolled

Show 1 more trial

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fed Condition

Completed·PPanacea Biotec Ltd·N/A·NCT01080417·84 enrolled

Lymphoma4 trials

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT00882895·18 enrolled

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00387959·17 enrolled

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01434472·20 enrolled

Show 1 more trial

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00574496·25 enrolled

Renal Transplant4 trials

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)

Completed·IIrmandade Santa Casa de Misericórdia de Porto Alegre·Phase 4·NCT01822483·100 enrolled

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

Completed·UUniversity of Washington·Phase 2·NCT00446459·45 enrolled

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Terminated· Novartis logo

Novartis·Phase 4·NCT00658333·30 enrolled

Show 1 more trial

Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

Completed·UUniversity of Washington·Phase 2·NCT00446251·14 enrolled

Acute Lymphoblastic Leukemia4 trials

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00988715·17 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

Show 1 more trial

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01690520·163 enrolled

Hematological Malignancies4 trials

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03712878·10 enrolled

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01384513·40 enrolled

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

Show 1 more trial

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00566696·73 enrolled

Treatment3 trials

Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement

Recruiting·PPeking Union Medical College Hospital·N/A·NCT05789017·60 enrolled

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05306873·12 enrolled

Alipogene Tiparvovec for the Treatment of LPLD Patients

Withdrawn·UUniQure Biopharma B.V.·Phase 2·NCT02904772

Sickle Cell Disease3 trials

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Terminated·NNationwide Children's Hospital·Phase 2·NCT01279616·8 enrolled

A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruiting·—·Phase 1·NCT03249831·3 enrolled

Transplantation3 trials

Allogeneic Transplantation From Related Haploidentical Donors

Completed·SStanford University·Phase 2·NCT00185692·16 enrolled

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT03246906·150 enrolled

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Graft Versus Host Disease3 trials

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00089011·150 enrolled

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Completed·MMedical College of Wisconsin·Phase 3·NCT03959241·431 enrolled

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02208037·279 enrolled

Chronic Lymphocytic Leukemia3 trials

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00104858·66 enrolled

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00060424·21 enrolled

Acute Graft Versus Host Disease3 trials

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Completed·MMedical College of Wisconsin·Phase 3·NCT01002742·236 enrolled

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT01044745·20 enrolled

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00506948·13 enrolled

Heart Transplant3 trials

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Completed· Novartis logo

Novartis·Phase 4·NCT01266148·115 enrolled

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Not yet recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT06942156·140 enrolled

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00862979·162 enrolled

Nephrotic Syndrome2 trials

Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Recruiting·—·Phase 2·NCT05843968·46 enrolled

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Terminated·IIstituto Giannina Gaslini·Phase 2·NCT04402580·30 enrolled

Kidney2 trials

Shift to Everolimus (RAD) Kidney Sparing Study

Terminated·UUniversity of Bologna·Phase 4·NCT00420537·34 enrolled

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Completed·UUniversity of Miami·Phase 2·NCT00533442·170 enrolled

Prevention2 trials

Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention

Completed·UUniversity of Pittsburgh·Phase 2·NCT01487577·19 enrolled

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Completed·—·Phase 3·NCT01951885·101 enrolled

Thalassemia2 trials

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT03171831·30 enrolled

Fanconi Anemia2 trials

TBI Dose De-escalation for Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00352976·83 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00093743·2 enrolled

Myelofibrosis2 trials

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03426969·3 enrolled

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04384692·53 enrolled

Hepatitis2 trials

A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

Completed·SSouthern California Institute for Research and Education·Phase 2·NCT01903798·4 enrolled

Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06789315·60 enrolled

Aplastic Anemia2 trials

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06752694·20 enrolled

Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00005935·130 enrolled

Fasting Conditions2 trials

Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions

Completed·—·Phase 1·NCT01283867·92 enrolled

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00911274·53 enrolled

Bone Marrow Transplant2 trials

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134004·210 enrolled

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01532635·4 enrolled

Neuromyelitis Optica2 trials

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT02809079·100 enrolled

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Not yet recruiting·IImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.·Phase 1/2·NCT06557174·116 enrolled

Kidney Cancer2 trials

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00243009·1 enrolled

Pemphigus Vulgaris2 trials

A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)

Unknown status·TTongji Hospital·Phase 4·NCT05303272·60 enrolled

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Completed· Roche logo

Roche·Phase 3·NCT02383589·135 enrolled

Severe Aplastic Anemia2 trials

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00354419·30 enrolled

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06412497·60 enrolled

Safety and Efficacy2 trials

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

Terminated·MMatthew Cooper·Phase 2/3·NCT01878786·25 enrolled

Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts

Completed·UUniversity of Cincinnati·Phase 4·NCT00374647·17 enrolled

Systemic Lupus Erythematosus2 trials

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Terminated· Roche logo

Roche·Phase 3·NCT00626197·381 enrolled

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT01101802·71 enrolled

Hematologic Disease2 trials

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06013423·54 enrolled

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00719888·135 enrolled

Stem Cell Transplantation2 trials

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

Terminated·NNew York Medical College·Phase 1·NCT00669890·12 enrolled

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00044954

Allogeneic Stem Cell Transplantation2 trials

Allogeneic Stem Cell Transplantation for Children With CML

Completed·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT02707393·13 enrolled

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807606·35 enrolled

Hematopoietic Cell Transplantation2 trials

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT04904588·300 enrolled

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Completed·SStanford University·Phase 2·NCT03734601·22 enrolled

Multiple Myeloma2 trials

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02447055

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Completed·WWen-Kai Weng·Phase 2·NCT00185614·63 enrolled

Combination Therapy2 trials

Combination Therapy Using Cellcept and Rebif in RRMS

Completed·AAaron Boster·Phase 1·NCT00618527·31 enrolled

A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

Completed· Roche logo

Roche·Phase 3·NCT02091414·36 enrolled

Limited Cutaneous Systemic Sclerosis1 trial

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

Unknown status·UUniversity College, London·Phase 2·NCT04927390·120 enrolled

Melanoma1 trial

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006233

Heart Transplantation1 trial

Belatacept in De Novo Heart Transplantation

Recruiting·NNYU Langone Health·Phase 2·NCT04477629·12 enrolled

Leukemia1 trial

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01041508·18 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled

Monoclonal1 trial

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

Completed· Astellas logo

Astellas·Phase 2·NCT00693524·94 enrolled

Allograft1 trial

Belatacept Therapy for the Failing Renal Allograft

Completed·AAndrew B Adams·Phase 3·NCT01921218·13 enrolled

Completed·UUniversity Medical Center Groningen·Phase 3·NCT00103792·84 enrolled

Systemic Sclerosis1 trial

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06375005·38 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Small Cell Lung Cancer1 trial

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Terminated·WWashington University School of Medicine·Phase 1·NCT05049863·17 enrolled

Telitacicept1 trial

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Unknown status·FFen Li·Phase 4·NCT05666336·30 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Completed·—·Phase 4·NCT02677181·100 enrolled

Bone Marrow Transplantation1 trial

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00303719·342 enrolled

Hematological Diseases1 trial

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00309842·213 enrolled

Juvenile Neuronal Ceroid Lipofuscinosis1 trial

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Completed·UUniversity of Rochester·Phase 2·NCT01399047·19 enrolled

Gastrointestinal1 trial

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Terminated·UUniversity of Pennsylvania·Phase 4·NCT00522548·37 enrolled

aGVHD Prophylaxis1 trial

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Recruiting·LLeland Metheny·Phase 2·NCT06680661·20 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Hemoglobinopathies1 trial

Allo HSCT for High Risk Hemoglobinopathies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06872333·62 enrolled

Gut Microbiome1 trial

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Active, not recruiting·OOslo University Hospital·Phase 4·NCT04207177·100 enrolled

HIV1 trial

MMF for HIV Reservoir Reduction

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT03262441·5 enrolled

Severe Combined Immunodeficiency1 trial

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008450·6 enrolled

Pterygium1 trial

Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 3·NCT02187900·300 enrolled

Immunosuppression1 trial

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00141037·130 enrolled

Adult Subject1 trial

A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01711489·24 enrolled

Tics1 trial

Pharmacokinetics of Mmf and Valganciclovir

Completed·UUniversity of Michigan·Phase 4·NCT00189150·16 enrolled

Scleroderma1 trial

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

Completed·UUniversity of California, San Francisco·N/A·NCT00333437·7 enrolled

Interstitial Lung Disease1 trial

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease

Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT02896205·41 enrolled

Chronic Myelogenous Leukemia1 trial

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Myelodysplastic Syndrome1 trial

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Active, not recruiting·—·Phase 2·NCT04262843·33 enrolled

Total Body Irradiation1 trial

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Completed·VVirginia Commonwealth University·Phase 2·NCT00709592·42 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Pancreatic Cancer1 trial

Study of CellCept for Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT00997958·12 enrolled

CIDP1 trial

Interest of Mycophenolate for CIDP Weaning

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02494505·40 enrolled

Pediatric Heart Transplantation1 trial

Alloantibodies in Pediatric Heart Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT01005316·290 enrolled

Tocilizumab1 trial

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Non-malignant Disorders1 trial

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04644016·31 enrolled

Immune Thrombocytopenia1 trial

Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate

Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 3·NCT03156452·123 enrolled

Acute Myeloid Leukemia1 trial

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Immunodeficiency1 trial

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00553098·29 enrolled

Uveitis1 trial

Methotrexate and Mycophenolate Mofetil for UVEITIS

Completed·UUniversity of California, San Francisco·Phase 3·NCT01829295·216 enrolled

Primary Biliary Cholangitis1 trial

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Unknown status·WWest China Hospital·Phase 4·NCT04376528·89 enrolled

Homeostasis1 trial

Tolerance by Engaging Antigen During Cellular Homeostasis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03504241·8 enrolled

Natural Killer Cell1 trial

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Recurrent or Refractory1 trial

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04530487·1 enrolled

Donor1 trial

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02582775·17 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06001385·313 enrolled

Granuloma1 trial

Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001764·50 enrolled

IgA Nephropathy1 trial

Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy

Unknown status·YYonsei University·Phase 4·NCT02981212·100 enrolled

Cardiac Transplant1 trial

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Completed· Roche logo

Roche·Phase 4·NCT00048165·434 enrolled

Transplant Recipient1 trial

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Terminated· Roche logo

Roche·Phase 4·NCT00121784·12 enrolled

Withdrawal1 trial

MMF and Calcineurin Inhibitor Withdrawal in CAN

Terminated·UUniversity Hospital Muenster·N/A·NCT00204230·86 enrolled

Myasthenia Gravis1 trial

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Completed· Roche logo

Roche·Phase 3·NCT00408213·136 enrolled

Multiple Sclerosis1 trial

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00324506·43 enrolled

Unspecified3 trials

Intra-Osseous Co-Transplant of UCB and hMSC

Completed·—·Phase 1·NCT02181478·6 enrolled

A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).

Completed· Roche logo

Roche·Phase 2·NCT01292226·45 enrolled

Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fasting Condition

Completed·PPanacea Biotec Ltd·N/A·NCT01080443·56 enrolled

Regulatory

FDA Approval Timeline[5]

May 3, 1995

CELLCEPT

NDA NDA050722

Jun 19, 1997

CELLCEPT

NDA NDA050723

Aug 12, 1998

CELLCEPT

NDA NDA050758

Oct 1, 1998

CELLCEPT

NDA NDA050759

May 1, 2024

MYHIBBIN

NDA NDA216482

Sources

References

[1]
ClinicalTrials.gov — 616 trial records for Mycophenolate Mofetil. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — CellCept drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Mycophenolate Mofetil compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Mycophenolate Mofetil. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216482). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for CellCept. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Inosine-5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Roche

Patent Landscape[6]

Patent Cliff

Aug 16, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12194143Aug 16, 2039

12097285Aug 16, 2039

12226526Aug 16, 2039

11931455Aug 16, 2039

12097284Aug 16, 2039

CellCept

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Kidney Transplant20 trials

Lupus Nephritis9 trials

Liver Transplant9 trials

Stem Cell Transplant8 trials

Hematologic Malignancies5 trials

Hematologic Cancer4 trials

Fed4 trials

Lymphoma4 trials

Renal Transplant4 trials

Acute Lymphoblastic Leukemia4 trials

Hematological Malignancies4 trials

Treatment3 trials

Sickle Cell Disease3 trials

Transplantation3 trials

Graft Versus Host Disease3 trials

Chronic Lymphocytic Leukemia3 trials

Acute Graft Versus Host Disease3 trials

Heart Transplant3 trials

Nephrotic Syndrome2 trials

Kidney2 trials

Prevention2 trials

Thalassemia2 trials

Fanconi Anemia2 trials

Myelofibrosis2 trials

Hepatitis2 trials

Aplastic Anemia2 trials

Fasting Conditions2 trials

Bone Marrow Transplant2 trials

Neuromyelitis Optica2 trials

Kidney Cancer2 trials

Pemphigus Vulgaris2 trials

Severe Aplastic Anemia2 trials

Safety and Efficacy2 trials

Systemic Lupus Erythematosus2 trials

Hematologic Disease2 trials

Stem Cell Transplantation2 trials

Allogeneic Stem Cell Transplantation2 trials

Hematopoietic Cell Transplantation2 trials

Multiple Myeloma2 trials

Combination Therapy2 trials

Limited Cutaneous Systemic Sclerosis1 trial

Melanoma1 trial

Heart Transplantation1 trial

Leukemia1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Monoclonal1 trial

Allograft1 trial

Medication1 trial

Sts1 trial

Microscopic Polyangiitis1 trial

Systemic Sclerosis1 trial

Brain Cancer1 trial

Small Cell Lung Cancer1 trial

Telitacicept1 trial

Efficacy and Safety1 trial

Bone Marrow Transplantation1 trial

Hematological Diseases1 trial

Juvenile Neuronal Ceroid Lipofuscinosis1 trial

Gastrointestinal1 trial

aGVHD Prophylaxis1 trial

Genetic Disorder1 trial

Hemoglobinopathies1 trial

Gut Microbiome1 trial

HIV1 trial

Severe Combined Immunodeficiency1 trial

Pterygium1 trial

Immunosuppression1 trial

Adult Subject1 trial

Tics1 trial

Scleroderma1 trial

Interstitial Lung Disease1 trial

Chronic Myelogenous Leukemia1 trial